<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">8611382</article-id><article-id pub-id-type="pmc">2074366</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Experience with poorly myelosuppressive chemotherapy schedules for advanced myeloma. The Cooperative Group of Study and Treatment of Multiple Myeloma.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Brugnatelli</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Riccardi</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ucci</surname><given-names>G.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mora</surname><given-names>O.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Barbarano</surname><given-names>L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Piva</surname><given-names>N.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Piccinini</surname><given-names>L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bergonzi</surname><given-names>C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>De Paoli</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Di Stasi</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Rinaldi</surname><given-names>E.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Trotti</surname><given-names>G.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Petrini</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ascari</surname><given-names>E.</given-names></name></contrib></contrib-group><aff>Medicina Interna ed Oncologia Medica, Universita and Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S. Matteo, Pavia, Italy.</aff><pub-date pub-type="ppub"><month>3</month><year>1996</year></pub-date><volume>73</volume><issue>6</issue><fpage>794</fpage><lpage>797</lpage><abstract><p>In a multicentre study, 83 patients with advanced and previously uniformly treated multiple myeloma (MM) were randomised between cyclophosphamide (600 mg m-2) and epirubicin (70 mg m-2), administered every 3 weeks for three courses and both associated with prednisone and interferon-alpha2b. Both regimens were administered on an outpatient basis and had low haematological toxicity. Clinical results were similar. Overall response rate (43%) and median response and survival (5.9 and 14.1 months respectively) compare well with those obtained with more aggressive chemotherapy schedules.</p></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="brjcancer00034-0084.tif" xlink:title="scanned-page" xlink:role="794" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00034-0085.tif" xlink:title="scanned-page" xlink:role="795" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00034-0086.tif" xlink:title="scanned-page" xlink:role="796" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00034-0087.tif" xlink:title="scanned-page" xlink:role="797" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

